AETHLON MEDICAL INC
Close on Oct 19, 2026
- Market cap
- $1.99M
- P/E (TTM)
- –
- Dividend yield
- –
About Aethlon Medical
Surgical & Medical Instruments & Apparatus, SIC 3841
Aethlon Medical, Inc. is a medical therapeutic company engaged in developing the Hemopurifier, a clinical-stage investigational immunotherapeutic device. The device uses lectin-based technology to bind and clear enveloped viruses and extracellular vesicles from biological fluids, targeting unmet clinical needs in oncology, life-threatening viral infections, and organ transplantation. Within oncology, the company focuses on removing disease-associated extracellular vesicles to counteract immune suppression and tumor metastasis in patients with advanced or metastatic solid tumors undergoing anti-PD-1 monotherapy.
The company operates a wholly-owned subsidiary in Australia that conducts clinical trials across three study sites located in Adelaide, Sydney, and the Gold Coast. Aethlon Medical also maintains an investigational device exemption for viral applications covering protocols in the United States and Canada, and operates research and manufacturing facilities in San Diego, California, where its corporate headquarters and executive offices are located.
Summary of the business section of Aethlon Medical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- AETHLON MEDICAL INC
- Founded
- 1999
- Headquarters
- San Diego, CA
- Address
- 11555 Sorrento Valley Road, Suite 203 92121
- Phone
- (619) 941-0360
- Website
- aethlonmedical.com
- Employees
- 9, Mar 31, 2026
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Nevada
- Fiscal year ends
- March 31
- Auditor
- HASKELL & WHITE LLP, Irvine, California
Stock & identifiers
- Ticker
- AEMD
- Exchange
- Nasdaq
- Shares outstanding
- 1M, Aug 10, 2026
- Public float
- $5.67M, Sep 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-5 reverse, Aug 4, 2026; 1-for-10 reverse, Nov 12, 2025; 1-for-10 reverse, Oct 20, 2025; 1-for-8 reverse, Jun 26, 2025; 1-for-8 reverse, Jun 9, 2025; 1-for-10 reverse, Nov 14, 2023; 1-for-10 reverse, Oct 5, 2023; 1-for-15 reverse, Nov 1, 2019; 1-for-15 reverse, Oct 15, 2019; 1-for-50 reverse, Jul 13, 2015; 1-for-50 reverse, Apr 14, 2015
- SEC CIK
- 882291
- CUSIP
- 00808Y703
- ISIN
- US00808Y7031
- LEI
- 54930036LMXCIW3XG337
- EIN
- 13-3632859
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Chetan Shah | Director | 20,840 |
| Nicolas Gikakis | Director | 20,663 |
| Edward G. Broenniman | Director | 22,363 |
| Angela Rossetti | Director | 26,207 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 Charles JFisher | $0 | $0 | $402.37K | $1 | – |
| FY2026 James BFrakes | $826.92K | $826.66K | $402.37K | $1 | – |
| FY2025 Charles JFisher | $0 | $0 | $437.84K | $9 | – |
| FY2025 James BFrakes | $500.00K | $495.40K | $437.84K | $9 | – |
| FY2024 Charles JFisher | $505.33K | $395.25K | $404.03K | $44 | – |
| FY2024 James BFrakes | $416.45K | $400.50K | $404.03K | $44 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of June 8, 2026, we had 9 full-time employees and no part-time employees.”
Corporate history
Events identified from SEC filings